Cargando…

Effectiveness of pegylated interferon alfa plus HAART in HIV/HBV treatment-naïve coinfected patients

Detalles Bibliográficos
Autores principales:	Mata-Marín, JA, Arroyo-Anduiza, CI, Arias-Flores, R, Gaytán-Martínez, JE
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112991/ http://dx.doi.org/10.1186/1758-2652-13-S4-P207

Ejemplares similares

High prevalence of genotype G in HIV co-infected patients compared with HBV monoinfected patients in México
por: Mata-Marín, JA, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection
por: Macías, Juan, et al.
Publicado: (2015)

Risk factors and correlates for anemia in HIV treatment-naïve infected patients: a cross-sectional analytical study
por: Mata-Marín, José A, et al.
Publicado: (2010)

Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers
por: Costa, Marisa Boff, et al.
Publicado: (2018)

Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study
por: Mata-Marín, José Antonio, et al.
Publicado: (2009)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Quantitative HBsAg and HBeAg Predict Hepatitis B Seroconversion after Initiation of HAART in HIV-HBV Coinfected Individuals
por: Matthews, Gail V., et al.
Publicado: (2013)

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
por: Levent, Görenek, et al.
Publicado: (2006)

Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
por: Kim, Gun-Wook, et al.
Publicado: (2013)

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
por: Vogel, M, et al.
Publicado: (2010)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
por: Zheng, Caixia, et al.
Publicado: (2019)

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial
por: Mecenate, Fabrizio, et al.
Publicado: (2010)

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
por: Choi, Sang Bun, et al.
Publicado: (2011)

Transient Visual Loss in a Hepatitis C Patient Treated With Pegylated Interferon Alfa-2a and Ribavirin
por: Jancoriene, Ligita, et al.
Publicado: (2014)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Lichen Planus Induced by Pegylated Interferon Alfa-2a Therapy in a Patient Monitored for Delta Hepatitis
por: Kaya, Safak, et al.
Publicado: (2015)

Interstitial Pneumonitis Related to Pegylated Interferon Alfa-2a Treatment in a Patient with Chronic Hepatitis C
por: Alkan, Erhan, et al.
Publicado: (2016)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison
por: Andersohn, Frank, et al.
Publicado: (2016)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients
por: Bedimo, Roger, et al.
Publicado: (2016)

Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2
por: Liu, Jingyuan, et al.
Publicado: (2021)

Pegylated interferon-alfa-2a monotherapy in patients infected with HCV genotype 2 and importance of rapid virological response
por: Etoh, Reiko, et al.
Publicado: (2011)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020)

Formal reasoning on qualitative models of coinfection of HIV and Tuberculosis and HAART therapy
por: Sorathiya, Anil, et al.
Publicado: (2010)

Changes in serum Interleukin-33 concentration before and after treatment with pegylated interferon alfa-2a plus ribavirin in patients with chronic hepatitis C genotype 1b infection
por: Cacopardo, Bruno, et al.
Publicado: (2012)

Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
por: Aghemo, Alessio, et al.
Publicado: (2011)

Impact of HCV viremia on HBV biomarkers in patients coinfected with HBV and HCV
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

Mexican patients with HIV have a high prevalence of vertebral fractures
por: Mata-Marín, José Antonio, et al.
Publicado: (2018)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin
por: Szymanek-Pasternak, Anna, et al.
Publicado: (2016)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Prevalence of cytopenias in both HAART and HAART naïve HIV infected adult patients in Ethiopia: a cross sectional study
por: Fekene, Tamirat Edie, et al.
Publicado: (2018)

Chances for cure in chronic HBV/HDV coinfection
por: Iliescu, Gabriela, et al.
Publicado: (2014)

Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus
por: Kim, Yu Jin, et al.
Publicado: (2011)

HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons
por: Bihl, Florian, et al.
Publicado: (2015)

Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis
por: Luo, Aoran, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u5nss76eicp4b77sbmonq889tn